OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights Nov 15, 2022 07:00AM
OmniAb Announces Completion of Spin-Off and Business Combination Nov 1, 2022 04:01PM
Ligand Pharma (LGND) Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI for Treatment of Patients with Relapsed or Refractory Multiple Myeloma Oct 26, 2022 08:01AM
Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Oct 26, 2022 08:00AM
OmniAb Business Combination Approved by APAC Shareholders (AHPA) Oct 24, 2022 05:04PM


Oct 24, 2022 05:00PM OmniAb Business Combination Approved by APAC Shareholders
Oct 3, 2022 09:00AM Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off
Aug 24, 2022 05:01PM Ligand Pharma (LGND) Announces that Janssen has Received Approval from EC for TECVAYLI
Aug 24, 2022 05:00PM Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Aug 8, 2022 04:01PM Ligand Reports Second Quarter 2022 Financial Results
May 4, 2022 04:01PM Ligand Reports First Quarter 2022 Financial Results